BCR-ABL1 Inhibitors
1 drugsAbout BCR-ABL1
BCR-ABL1 is a tyrosine kinase protein resulting from the Philadelphia chromosome translocation, leading to a fusion gene with constitutively active tyrosine kinase activity. This unregulated activity drives uncontrolled cell proliferation, particularly in certain blood cancers.
BCR-ABL1 is a crucial target for drug development due to its role in specific blood cancers. Currently, there is no genetic evidence data available to further illuminate the link between BCR-ABL1 and disease.
BCR-ABL1 is targeted by one FDA-approved therapy, SCEMBLIX, a small molecule inhibitor developed by Novartis. This drug falls into the 'other' therapeutic area category.
Top BCR-ABL1 Drugs
Novartis is the only company with an approved drug targeting BCR-ABL1.
The lack of competition suggests high barriers to entry or limited market potential.
BCR-ABL1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BCR-ABL1, using small molecule modality.
The modality landscape suggests an opportunity to explore alternative modalities like antibodies or PROTACs.
BCR-ABL1 Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BCR-ABL1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 1 | 0 | 5 | 100% |
| Phase 2 | 9 | 1 | 2 | 6 | 33% |
| Phase 3 | 4 | 1 | 1 | 2 | 50% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BCR-ABL1 Drug Approval Timeline (2021 - 2021)
The first and only drug targeting BCR-ABL1, SCEMBLIX, was approved in 2021.
The recent approval and lack of subsequent approvals indicates a potentially unsaturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BCR-ABL1. A trial counts if an approved drug acting on BCR-ABL1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.